UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Median OS not reached in metastatic prostate cancer treated with investigational SV-102, phase I study finds

Median overall survival has not been reached in the phase I study of SYNC-T Therapy SV-102, an investigational multi-target immunotherapy platform for solid tumors in patients with metastatic prostate cancer, as of the April 1 data cutoff.

Perioperative apalutamide reduces risk of death and metastasis in high-risk localized or locally advanced prostate cancer, study finds

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

Researchers identify critical window for boosting immunotherapy response in prostate cancer, Roswell Park-led study finds

A team of researchers has shown that hormone-blocking therapies commonly used to treat prostate cancers temporarily activate the body’s immune response before those immune effects begin to fade over time.

Routine breast imaging may offer little benefit after double mastectomy for early breast cancer, UCLA-led study finds

Women who have undergone a double mastectomy to treat ductal carcinoma in situ, a noninvasive form of breast cancer also known as stage 0 breast cancer, may not benefit from routine mammograms or other breast imaging after surgery, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.